Moreover, CRC tumor‐derived IL‐6 increases the phagocytic potential and migration of THP‐1 cells and human monocytes through STAT3 phosphorylation, thus suggesting that IL‐6 secretion by CRC cells can increase the phagocytic and migratory potential of macrophages in the TME and serve as a therapeutic option for CRC treatment [232]. This evidence concerns the gene STAT3 and colorectal carcinoma.